Table 1.
Patient characteristics by diagnosis.
| Control n = 27 | CD n = 116 | |
|---|---|---|
| Age, mean (SD) | 45.2 (12.0) | 40.6 (13.0) |
| Male Gender, n (%) | 10 (37.0%) | 58 (50.0%) |
| Body Mass Index, mean (SD) | 28.0 (5.8) | 28.0 (6.6) |
| Tobacco Use, n (%) | 2 (7.4%) | 15 (12.9%) |
| Any IBD Therapy, n (%) | — | 106 (91.4%) |
| 5-ASA alone, n (%) | — | 6 (5.2%) |
| Corticosteroid use, n (%) | — | 12 (10.3%) |
| Immunomodulator alone, n (%) | — | 14 (12.1%) |
| Anti-TNF-α alone, n (%) | — | 42 (36.2%) |
| Anti-TNF-α + Immunomodulator Combination Therapy, n (%) | — | 34 (29.3%) |
| Vedolizumab, n (%) | — | 1 (0.9%) |
| Ustekinumab, n (%) | — | 6 (5.2%) |
| IBD Related Surgery, n (%) | — | 63 (54.3%) |
| Ileo-colic Resection, n (%) | — | 30 (25.9%) |
| Small Bowel Resection, n (%) | — | 8 (6.9%) |
| Colectomy, n (%) | — | 3 (0.9%) |
| Multiple Surgeries, n (%) | — | 22 (19.0%) |
| Stricturing Phenotype, n (%) | — | 50 (43.1%) |
| Penetrating Phenotype, n (%) | — | 35 (30.2%) |
| Perianal Disease, n (%) | — | 38 (32.8%) |
| Years of Crohn’s Disease, mean (SD) | — | 11.67 (9.92) |
| Small Bowel Disease, n (%) | — | 44 (37.9%) |
| Large Bowel Disease, n (%) | — | 15 (12.9%) |
| Small and Large Bowel Disease, n (%) | — | 15 (12.9%) |
| Upper GI Involvement, n (%) | — | 9 (7.8%) |
Age and Body Mass Index (BMI) are represented by mean (SD) and were analyzed by the Mann-Whitney U test. Categorical variables are represented by number (%) and were analyzed using the Pearson’s χ2 test. Age, BMI, gender, and tobacco use were not significantly different from control.